# A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

> **NCT04877288** · PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 102 (estimated)

## Conditions studied

- Renal Allograft Recipients

## Interventions

- **BIOLOGICAL:** Belatacept
- **DRUG:** Tacrolimus
- **DRUG:** Cyclosporine A
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Enteric Coated Mycophenolate Sodium
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT04877288
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-21
- **Primary completion:** 2032-12-30
- **Final completion:** 2034-06-30
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04877288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04877288, "A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04877288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*